FDA accepts two of MSD’s new drug applications
MSD has announced that the US Food and Drug Administration (FDA) has accepted for review New Drug Applications (NDA) for two of its antibacterial agents.
Read More
Tag: MK-7655A
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
